Lowering von Willebrand factor as a therapeutic approach to reduce the risk of thrombosis

Cardiovascular disease is one of the leading causes of death. Individuals with high von Willebrand factor (VWF) levels have an increased risk of coronary heart disease, ischemic stroke, venous thrombosis, and also cardiovascular mortality. Genetic variations in VWF have been associated with VWF levels and increased risk of coronary heart disease and ischemic stroke. The causal role of VWF is further substantiated by the reduced risk of arterial thrombosis in patients with von Willebrand disease (VWD) and low VWF levels. In this project we aim to develop a strategy for lowering VWF levels as a potential therapy to reduce thrombosis risk.